Manufacturing Process to Scale Nanoparticle Synthesis
Project Overview
One Liner: The project aims to develop a manufacturing process that scales synthesis to the gram-scale, automates purification, reduces time and labor required, and enables an eventual translation to GMP manufacturing
Company: Drexel University - Rodell Lab
Cyclodextrin nanoparticles (CDNPs) are novel drug delivery particles that aid in macrophage targeting for patients suffering from inflammatory diseases. 62 million people per year suffer from inflammatory diseases, costing the nation approximately 306.8 billion dollars per year. So, CDNP targeting would help deliver drugs directly the cell, enabling proper healing and treatment. Currently, CDNP synthesis requires two days of labor-intensive work over about 7 hours. The lab is also limited by the amount they can make, as the limit of a single batch is 100 mg. Concurrent batches in one run can get up to about 800 mg, but increase the labor proportionally and make it harder to create accurately sized nanoparticles. So, our objective is to develop a GMP-translatable manufacturing process for cyclodextrin nanoparticles that scales up synthesis to the grams level, automates purification, and maintains uniformity of size while reducing the labor and time required to perform the synthesis and purification.
No video available.
Screenshots
0 image(s)No screenshots uploaded yet.